Daniel Ayan

Daniel Ayan leads translational efforts in pharmaceutical drug combination development, designing clinical combination strategies that integrate preclinical synergy data, pharmacokinetic modeling, and biomarker-driven patient selection to optimize the clinical development of anti-cancer drug combinations. His work at AstraZeneca has established frameworks for translating preclinical combination synergy findings into clinical trial designs that maximize the probability of demonstrating clinical benefit while managing overlapping toxicities. His translational research bridges the gap between laboratory combination discovery and clinical combination therapy implementation.